Christopher Moxham
Chief Executive Officer bij Rarebase, PBC
Profiel
Dr. Christopher Moxham is a Chief Executive & Scientific Officer at Transcripta Bio, Inc. and a President & Chief Executive Officer at Rarebase, PBC.
Dr. Moxham was previously employed as a Chief Scientific Officer by Fulcrum Therapeutics, Inc. and a Head-Drug Discovery by Eli Lilly & Co.
He received his undergraduate degree from Cornell University and a doctorate degree from Stony Brook University.
Actieve functies van Christopher Moxham
| Bedrijven | Functie | Begin |
|---|---|---|
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Chief Executive Officer | 04-10-2023 |
Eerdere bekende functies van Christopher Moxham
| Bedrijven | Functie | Einde |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Christopher Moxham
| Stony Brook University | Doctorate Degree |
| Cornell University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
